Assessing and managing adverse events to immunotherapies

In this video interview, Brenda Martone discusses the clinical nurse specialist’s role in assessing and managing immune-related complications and toxicities associated with immune checkpoint inhibitors, such as nivolumab, ipilimumab and pembrolizumab. Brenda notes that immune-related reactions may occur months after a single dose of the immune checkpoint inhibitors. Immune-related reactions may include diarrhoea and colitis, issues with the heart muscle (cardiomyopathies), skin rashes and thyroid issues. It is important to monitor patients closely even after therapy has been discontinued to assess for immune-related toxicities.

Watch the video interview on UroToday here

Share this Post!


Related post

  TOP